Dogwood Therapeutics DWTX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| —— | —— | —— | —— | —— | ||
| $22.1M+293% | $21.87M+519% | $21.84M+1,343% | $7.86M+481% | $5.62M+257% | ||
| $6.52M-33.0% | $6.1M-29.8% | $9.86M+129% | $10.34M+200% | $9.72M+168% | ||
| $28.61M+86.5% | $27.97M+129% | $31.7M+444% | $18.2M+279% | $15.34M+195% | ||
| $28.61M+86.5% | $27.97M+129% | $31.7M+444% | $18.2M+279% | $15.34M+195% | ||
| -$28.61M-86.5% | -$27.97M-129% | -$31.7M-444% | -$18.2M-279% | -$15.34M-195% | ||
| $321.38K+223% | $96.94K+205% | -$110.57K-213% | -$170.66K-246% | -$262.05K-297% | ||
| $269.93K+104% | -$6.13M-4,881% | -$6.31M-6,528% | -$6.35M-5,535% | -$6.45M-4,941% | ||
| —— | —— | —— | —— | —— | ||
| —— | -$2.73K— | —— | —— | —— | ||
| -$28.29M-29.8% | -$34.04M-176% | -$38.02M-564% | -$24.55M-425% | -$21.79M-330% | ||
| -$28.32M-28.8% | -$34.26M-177% | -$38.2M-567% | -$24.74M-429% | -$21.98M-334% | ||
| —— | —— | -$26.21-316% | -$20.06-242% | -$19.22-300% | ||
| —— | —— | -$26.21-316% | -$20.06-242% | -$19.22-300% | ||
| 42.4M+842% | 10.2M+168% | 6.3M+77.6% | 5.5M+71.5% | 4.5M-78.3% | ||
| 42.4M+842% | 10.2M+168% | 6.3M+77.6% | 5.5M+71.5% | 4.5M-78.3% | ||
| $321.38K+223% | $96.94K+205% | -$110.57K-213% | -$170.66K-246% | -$262.05K-297% | ||
| -$26.24M-1.8% | -$30.98M-91.1% | -$39.84M-570% | -$25.01M-401% | -$25.79M-390% | ||
| $31.75K-83.3% | $221.1K+44,055% | $188.75K— | $190.19K— | $190.04K— | ||
| —— | —— | -$43.95K— | -$34.14K— | -$46.36K— | ||
| —— | -$2.73K— | —— | —— | —— | ||
| $269.93K+104% | -$6.13M-4,881% | -$6.31M-6,528% | -$6.35M-5,535% | -$6.45M-4,941% | ||
| —— | —— | —— | —— | -$1.64M— | ||
| -$28.61M-86.5% | -$27.97M-129% | -$31.7M-444% | -$18.2M-279% | -$15.34M-195% | ||
| —— | —— | —— | -$18.16M— | -$15.32M— | ||
| -$28.61M-86.5% | -$27.97M-129% | -$31.7M-444% | -$18.2M-279% | -$15.34M-195% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Dogwood Therapeutics profitable?
- Dogwood Therapeutics is not currently profitable: it reported a net loss of $28.3M over the trailing twelve months.
- What is Dogwood Therapeutics's earnings per share?
- Dogwood Therapeutics's diluted EPS over the trailing twelve months is $-18.79.
- Where does Dogwood Therapeutics's income statement data come from?
- Every line is extracted from Dogwood Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.